NOVO NORDISK’S NEWCOMER VS. ELI LILLY'S OFFERING: A HEAD-TO-HEAD COMPARISON

Both this new medication and tirzepatide represent significant breakthroughs in metabolic disorder treatment, but their mechanisms of action and initial clinical findings present key distinctions. Retatrutide functions as a dual GIP and GLP-1 receptor agonist, while tirzepatide also acts on both